Filtered By:
Condition: Heart Failure
Nutrition: Sodium

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 255 results found since Jan 2013.

The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management
This article provides an overview of recent evidence of benefits on cardiovascular (CV) outcomes.Recent FindingsThe recently published phase III FIDELIO-DKD and FIGARO-DKD, alone and pooled, in patients with CKD and diabetes demonstrate that finerenone reduces the composite of CV death, non-fatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure (HF) with hospitalization for HF being the primary driver of this composite.SummaryFinerenone is indicated to reduce renal and CV outcomes in patients with CKD and diabetes. Future investigations of this agent include patients with non-diabetic CKD, HF w...
Source: Current Cardiology Reports - October 22, 2022 Category: Cardiology Source Type: research

Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER
CONCLUSIONS: In DAPA-HF and DELIVER, the response to dapagliflozin was similar between men and women. Sex did not modify the treatment effect of dapagliflozin across the range of ejection fraction.PMID:36342789 | DOI:10.1161/CIRCULATIONAHA.122.062832
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Xiaowen Wang Muthiah Vaduganathan Brian L Claggett Sheila M Hegde Maria Pabon Ian J Kulac Orly Vardeny Eileen O'Meara Shelley Zieroth Tzvetana Katova Martina M McGrath Anne-Catherine Pouleur Pardeep S Jhund Akshay S Desai Silvio E Inzucchi Mikhail N Kosib Source Type: research

Why Are Cardiologists Not Prescribing the New Diabetes Medications?
Randomized clinical trials and guidelines from multiple societies have established significant cardiovascular (CV) outcome benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D). Among patients with T2D, those with known CV disease and those at high risk who are receiving metformin have lower risks of death, myocardial infarction, and stroke if they are treated with GLP-1RAs, and those treated with SGLT2is have reduced risks of hospital admission for heart failure, CV mortality, and all-cause mortality.
Source: The American Journal of Cardiology - December 14, 2022 Category: Cardiology Authors: Lloyd W. Klein Source Type: research

Disparities in Adoption of New Diabetic Therapies with Cardiovascular Benefits
Cardiovascular disease remains the most common cause of death among patients with diabetes [1 –3]. Two recently approved classes of medications for Type 2 diabetes mellitus (T2DM) reduce the risk of cardiovascular events. Glucagon-like peptide-1 agonists (GLP1RA) reduce death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke in patients T2DM[5–10]. Sodium-gl ucose co-transporter 2 inhibitors (SGLT2i) reduce heart failure events by 27% to 39% and decrease the frequency of worsening renal disease by 39% compared to placebo in patients with T2DM.
Source: Diabetes Research and Clinical Practice - December 26, 2022 Category: Endocrinology Authors: Elena C. Vasti, Marina Basina, Jamie Calma, David J. Maron, Fatima Rodriguez, Alexander T. Sandhu Source Type: research

Empagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in routine care in East Asia: Results from the EMPRISE study
ConclusionsThe results suggest that both empagliflozin and SGLT2i compared with DPP-4i are associated with a lower risk of cardiovascular events and all-cause mortality in routine clinical care in East Asia.
Source: Journal of Diabetes Investigation - January 31, 2023 Category: Endocrinology Authors: Dae Jung Kim, Wayne H ‐H Sheu, Wook‐Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Masaomi Nangaku, Elise Chia‐Hui Tan, Koichi Node, Atsutaka Yasui, Weiyu Lei, Sunwoo Lee, Laura Saarelainen, Anouk Deruaz‐Luyet, Moe H Kyaw, Yutaka Seino, EM Tags: ORIGINAL ARTICLE Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Conclusions/interpretationAt current prices, use of SGLT2is, but not GLP-1 RAs, would be cost-effective when considering only their cardiovascular and kidney disease benefits for people with type 2 diabetes.Graphical abstract
Source: Diabetologia - February 22, 2023 Category: Endocrinology Source Type: research

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research